1. Medtech Insight

Azar Tapped: Stakeholders Heap Praise On Trump HHS Nominee

The administration's nominee to head HHS is being praised by medtech health-care industry lobbyists but may experience some pushback in the Senate because of his ties to Eli Lilly.

As expected, President Trump nominated Alex Azar, a former Eli Lilly & Co. executive and Department of Health and Human Services official to the top post at HHS. The announcement was followed by a slew of accolades from medtech and health-care stakeholders. But Democrats in Congress are signaling plans to oppose the nomination.

One of the first to laud Azar's nomination was AdvaMed CEO Scott Whitaker who urged the Senate to confirm Azar swiftly, especially considering his experience in the private and public...

More from Leadership

More from Medtech Insight

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 
• By Natasha Barrow

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.